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Abstract
Oxidative stress plays an important role in the pathogenesis of neurodegenerative diseases, such as Parkinson’s disease. The
molecule, 2,3,5,49-tetrahydr- oxystilbene-2-O-b-D-glucoside (TSG), is a potent antioxidant derived from the Chinese herb,
Polygonum multiflorum Thunb. In this study, we investigated the protective effect of TSG against 6-hydroxydopamine-
induced apoptosis in rat adrenal pheochromocytoma PC12 cells and the possible mechanisms. Our data demonstrated that
TSG significantly reversed the 6-hydroxydopamine-induced decrease in cell viability, prevented 6-hydroxydopamine-
induced changes in condensed nuclei and decreased the percentage of apoptotic cells in a dose-dependent manner. In
addition, TSG slowed the accumulation of intracellular reactive oxygen species and nitric oxide, counteracted the
overexpression of inducible nitric oxide syntheses as well as neuronal nitric oxide syntheses, and also reduced the level of
protein-bound 3-nitrotyrosine. These results demonstrate that the protective effects of TSG on rat adrenal
pheochromocytoma PC12 cells are mediated, at least in part, by the ROS-NO pathway. Our results indicate that TSG may
be effective in providing protection against neurodegenerative diseases associated with oxidative stress.
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Introduction
Parkinson’s disease (PD), the second most common neurodegen-
erative disorder after Alzheimer’s disease (AD), is mainly charac-
terizedby progressive loss of dopaminergic(DAergic) neurons in the
substantia nigra pars compacta (SNpc) [1,2]. The cause of DAergic
neuron loss in PD patients remains unexplained. However, several
lines of evidence in PD patients and animal models have suggested
that oxygen-free radicals and oxidative stress are involved in the
pathogenesis of PD [3–5]. Thus, the regulation of oxidative stress
may reduce or prevent the loss of DAergic neurons in PD patients.
Medicinal herbs that have antioxidative effects are now being
considered as therapeutic agents against neuronal loss [6–8].
Six-Hydroxydopamine (6-OHDA), a hydroxylated analog of the
natural neurotransmitter, dopamine [9], can induce massive
oxidative stress leading to the damage of DAergic neurons in vitro
and in vivo [10–12]. PC12 cells, a cell line derived from rat adrenal
pheochromocytoma cells, possess intracellular substrates for
dopamine synthesis, metabolism and transport [10]. The apoptosis
of PC12 cells induced by 6-OHDA has been used as an in vitro
experimental model for the study of PD [13,14].
The root of Polygonum multiflorum Thunb (PM) is a widely used
traditional Chinese herbal medicine. Some studies have suggested
that PM and its extracts can be used to treat age-related diseases [15–
17]. A monomer of stilbene, 2,3,5,49-tetrahydroxy stilbene-2-O-b-D-
g l u c o s i d e( T S G )( F i g u r e1 )i so n eo ft h em a i na c t i v ei n g r e d i e n t so fP M
[18,19]. TSG has been reported to have many pharmacological
effects such as anti-oxidative and anti-inflammatory effects as well as
improving memory and learning ability [20–22]. Luo et al. have
shown that TSG may reduce the cognitive impairment and
overexpression of amyloid precursor protein induced by exposure
to aluminium and may have therapeutic effects against AD [23].
Moreover, TSG has been shown to possess neuroprotective effects
against ischemia/reperfusion injury in vitro and in vivo [24]. Recently,
our study group found that TSG may attenuate the 1-methyl-4-
phenylpyridinium-induced apoptosis of PC12 cells by inhibiting
reactive oxygen species (ROS) generation, and modulating the
activation of Jun N-terminal kinase (JNK) and the PI3K/Akt
pathway [25,26].
In order to further investigate the neuroprotective effect of TSG,
the present study aimed to evaluate the effects of TSG on PC12 cell
viability and apoptosis induced by 6-OHDA. Additionally, we
studied the possible mechanisms of TSG protection by measuring
intracellular ROS, intracellular nitric oxide (NO), protein levels of
inducible nitric oxide synthase (iNOS) and neuronal nitric oxide
synthase (nNOS) and the level of 3-nitrotyrosine (3-NT).
Materials and Methods
1. Materials
TSG (dissolved in distilled water, molecular weight 406, purity
.98%) was obtained from the National Institute for the Control of
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Hydroxydopamine hydrochloride (6-OHDA), 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetra-zoliumbromide (MTT) and Hoechst
33258 were purchased from Sigma (St. Louis, MO, USA).
Dulbecco’s modified Eagle’s medium (DMEM), fetal calf serum
and horse serum were purchased from Gibco (Gaithersburg, MD,
USA). Rabbit polyclonal antibodies to nNOS and to iNOS were
purchased from Abcam Company (Cambridge, UK). A 3-NT
ELISA kit was purchased from the Xitang Institute of Biotech-
nology (Shanghai, China). N
G-methyl-L-arginine acetate salt (L-
NMMA), glutathione (GSH), 3-amino-4-aminomethyl-29,79-di-
fluorescein diacetate (DAF-FM DA) and the Reactive Oxygen
Species Assay Kit were purchased from the Beyotime Institute of
Biotechnology (Shanghai, China).
2. Methods
2.1. Cell culture and treatment. PC12 cells are a cell line of
rat adrenal pheochromocytoma cells that possess dopamine
synthesis, metabolism and transporting system [26]. PC12 cells ,
kindly provided by People’s Liberation Army(PLA) Institute of
Neurobiology of the Fourth Military Medical University, were
cultured in DMEM supplemented with 10% heat-inactivated
horse serum, 5% heat-inactivated fetal calf serum, 100 IU/ml
penicillin and 100 mg/ml streptomycin. Culture medium was
changed every three days. PC12 cells were differentiated by
50 ng/mL nerve growth factor (NGF), which was added to the
culture medium and incubated for a further 9 days, as described
previously [27]. When cells reached 70% confluence, they were
passaged in a ratio of 1:3. In the experiments, cells were treated
with different concentrations of 6-OHDA (25, 50, 75, 100, 125,
150, 200, 300 mM) for 24 h to investigate the neurotoxicity of 6-
OHDA. TSG (10, 20, 50 mM) was added into cells for 24 h and
then incubated with 75 mM 6-OHDA for 24 h. Control cells were
treated in the same way without adding 6-OHDA and TSG to the
culture medium.
2.2. Exposure of PC12 cells to 6-OHDA with or without
test substances. Cell viability was measured by MTT assay.
PC12 cells were seeded in 96-well plates at a concentration of
1610
4 cells per well. After an overnight incubation, PC12 cells
were incubated with 6-OHDA for 24 h, and then washed with
phosphate buffer solution (PBS) three times. Following that, 20 ml
MTT solution (5 mg/ml in PBS) was added to each well and the
cells were incubated at 37uC for 4 h. The medium was then
removed, and 150 ml of dimethyl sulfoxide was added to dissolve
the blue crystals that formed in the cells. After being jolted by the
shaker for 15 min, the absorbance of the solution at 490 nm was
measured in a microplate reader (Bio-Rad, USA). Control cells
were treated in the same way without 6-OHDA treatment, and the
values of different absorbances were expressed as a percentage of
the control.
2.3. Staining of nuclear DNA in apoptotic cells with
Hoechst 33258. The changes in nuclear morphology of
apoptotic cells were examined by Hoechst 33258 staining and
visualized under a fluorescence microscope. After treatment with 6-
OHDA and/or TSG for 24 h, PC12 cells were fixed with 4%
paraformaldehyde for 30 min. Subsequently, PC12 cells were
washed three times with PBS, and incubated with 3 mg/mL
Hoechst 33258 for 30 min at room temperature in the dark. The
cells were observed under a fluorescence microscope (Olympus
IX71, Japan) after being washed twice with PBS. Cells that
exhibited reduced nuclear size, chromatin condensation, intense
fluorescence, and nuclear fragmentation were considered apoptotic.
2.4. Flow cytometric analysis of cell apoptosis. In order
to detect early apoptosis and late apoptosis/necrosis induced by 6-
OHDA quantitatively, cell apoptosis was measured using the
Annexin V-FITC Apoptosis Detection Kit (BD Pharmingen, USA)
according to the manual. Briefly, after treatment with 6-OHDA
and/or TSG for 24 h, PC12 cells were collected, washed, re-
suspended in 100 ml binding buffer, and stained with 5 ml annexin
V-FITC and 5 ml PI staining solution in the dark at room
temperature for 15 min. The cell samples were analyzed by flow
cytometry on a FACScan station with Cell Quest software using
the FL1 and FL2 range for annexin V-FITC and PI, respectively.
2.5. Measurement of intracellular ROS. ROS were
measured with the 29,79-dichlorofluorescein diacetate (DCFH-
DA) as previously described [28]. Briefly, after PC12 cells were
treated with 6-OHDA and/or TSG for 24 h, the cells were
washed three times with PBS. DCFH-DA, diluted to a final
concentration of 10 mM, was added to PC12 cells and these were
incubated for 30 min at 37uC in the dark. After the cells were
washed three times with serum-free medium, the fluorescence
intensity was detected with a multi-detection microplate reader
with excitation at 488 nm and emission at 530 nm within 15 min.
Control cells were treated in the same way without adding 6-
OHDA and TSG to the culture medium. The measured
fluorescence values were expressed as a percentage of the
fluorescence in control cells.
2.6. Measurement of intracellular NO. Intracellular NO
was measured with 3-amino,4-aminomethyl-29,79-difluorescein,
diacetate (DAF-FM DA), as previously described [29]. Briefly,
after PC12 cells were treated with 6-OHDA and/or TSG for 24 h,
the cells were washed three times with PBS and then incubated in
5 mM DAF-FM DA at 37uC for 20 min. After a further three PBS
washes, the fluorescence intensity was analyzed by a multi-
detection microplate reader with excitation at 495 nm and
emission at 515 nm within 15 min. The measured fluorescence
values were expressed as a percentage of the fluorescence in
control cells.
2.7. Measurement of protein-bound 3-NT. Protein-bound
3-NT was detected with the ELISA method according to the
manual. Briefly, a nitrated protein solution was prepared and
diluted for use as a standard. These standard samples and cell
samples were pipetted into 96-well plates and incubated with a
rabbit polyclonal anti-nitrotyrosine primary antibody at 37uC for
Figure 1. The chemical structure of TSG.
doi:10.1371/journal.pone.0026055.g001
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peroxidase-conjugated secondary antibody for 1 h and washed.
Subsequently, these samples were incubated with freshly prepared
LumiGLO Chemiluminescent Substrate for 10 min. Luminescence
was then measured with a microplate reader (Bio-Rad, USA). The
nitrotyrosine content in cell samples was calculated by standard
curves generated from nitrated bovine serum albumin containing
quantified nitrotyrosine amounts.
2.8. Western blot analysis of nNOS and iNOS. After PC12
cells were treated with 6-OHDA and/or TSG, cells were
solubilized with 56SDS (sodium dodecyl sulfate) loading buffer
(0.25 mM Tris-HCl, pH 6.8, containing 5% b-mercaptoethanol,
10% SDS, 50% glycerol, and 0.5% bromophenol blue) and boiled
for 5 min in 100uC water. Twenty microliters of each sample were
loaded into a lane of a 12% SDS-PAGE, and then
electrophoretically transferred to polyvinylidene fluoride (PVDF)
membranes. The membranes were blocked in blocking buffer (tris-
buffered saline tween TBST containing 5% non-fat milk) for 2 h
and incubated overnight with primary antibodies at 4uC. After
triplicate washes with PBS/Tween 20, the membranes were
incubated with secondary antibodies at 37uC for 2 h. Finally, the
membranes were developed with enhanced chemiluminescence
(ECL) substrate and exposed to X-ray film. Densitometry was
performed using WorkLab software (UVP, USA). The data were
recorded as the ratio of sample to b-actin.
3. Statistical analysis
All experiments were performed at least three times. Data are
expressed as mean 6 standard errors of mean (S.E.M.). Differences
were analyzed with one-way analysis of variance (ANOVA) with
subsequent post hoc analysis using Bonferroni differences where the
data were considered statistically significant (P,0.05).
Results
1. Effects of TSG on 6-OHDA-induced viability of PC12
cells
There was a dose-dependent decrease in cell viability following
6-OHDA exposure to PC12 cells (Figure 2A). Cell viability
significantly decreased by approximately 50% after PC12 cells
Figure 2. Effects of TSG and 6-OHDA on cell viability. Cells were incubated for 24 h in different concentrations of 6-OHDA alone (A) or in
different concentrations of TSG alone (B). Cells were preincubated with different concentrations of TSG (C) for 24 h or GSH (D) for 1 h, after which 6-
OHDA (75 mM) was added for 24 h. The data are expressed as percentage of untreated control cells 6 standard deviation (n=6). **P,0.01 versus
untreated control cells; # P,0.05, ## P,0.01 versus 6-OHDA-treated cells.
doi:10.1371/journal.pone.0026055.g002
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various concentrations of TSG alone for 24 h showed no obvious
effect on cell viability (Figure 2B). Conversely, cells treated with
various concentrations of TSG for 24 h before the addition of 6-
OHDA (75 mM) for 24 h showed that cell viability increased at
concentrations of 10, 20, and 50 mM TSG (Figure 2C). This
suggested that TSG has a positive effect on cell viability in a dose-
dependent manner. As shown in Figure 2D, GSH, a well-known
Figure 3. Fluorescence images show the nucleic changes of PC12 cells incubated in 6-OHDA with or without TSG. Cells were stained
with the DNA-binding fluorochrome Hoechst 33258. (A) shows normal culture medium nucleic morphology, (B) and (C) respectively show cells
cultured in 50 mM TSG or 75 mM 6-OHDA for 24 h. In addition, cells were pretreated with 10 mM (D), 20 mM (E) or 50 mM (F) TSG for 24 h and then
incubated in 6-OHDA (75 mM) for an additional 24 h. (G) Histograms showing ratio of condensed nuclei to total nuclei. White arrows represent
location of apoptosis cell. Scale bars represent 50 mm. **P,0.01 versus untreated control cells; ## P,0.01 versus 6-OHDA-treated cells.
doi:10.1371/journal.pone.0026055.g003
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OHDA-induced loss of cell viability in a dose-dependent manner.
2. Effects of TSG on 6-OHDA-induced changes in nuclear
morphology
Changes in nuclear morphology were tested by Hoechst 33258
staining. The normal nucleus showed a homogeneous staining,
bearing regular contors and rounded shapes (Figure 3A and B).
Most cells showed an asymmetrical, highly bright fluorescence,
and the number of condensed nuclei increased after exposed to
75 mM 6-OHDA for 24 h (Figure 3C). These changes in the
nuclear morphological character were prevented significantly by
pretreatment of cells with TSG (Figure 3D–F), especially at
concentrations of 20 mM (Figure 3E) and 50 mM (Figure 3F) TSG.
However, TSG alone had no effect on nuclear morphology
(Figure 3B).




- population is made up of normal healthy
cells, while annexin-V
+/PI
- cells exist in early apoptotic stage, and
annexin-V
+/PI
+ cells exist in late apoptotic/necrotic stage. After
24 h of incubation with 75 mM 6-OHDA, our results showed that
the percentage of early apoptosis increased significantly
(Figure 4C), and TSG showed a positive effect on apoptosis in a
dose-dependent manner (Figure 4D–F). TSG alone did not display
any obvious effect (Figure 4B).
4. Effects of TSG on intracellular ROS levels
As shown in Figure 5, exposure of PC12 cells to 75 mM6 -
OHDA for 24 h led to a 2.7-fold accumulation in the level of
intracellular ROS, compared with the control group (P,0.01).
Such accumulation in the level of intracellular ROS was
significantly reduced in a dose-dependent manner by pretreatment
of the cell with TSG. Additionally, TSG alone had no obvious
effect on intracellular ROS levels.
5. Effects of TSG on the levels of intracellular NO
Exposure of PC12 cells to 75 mM 6-OHDA for 24 h led to a
rapid increase in DAF-FM fluorescence, compared with the control
group (P,0.01) (Figure 6A). TSG (20 and 50 mM) pre-treatment
inhibited such increase in DAF-FM fluorescence, while TSG alone
had no effect on DAF-FM fluorescence intensity (Figure 6A). As
shown in Figure 6B, L-NMMA, a NOS inhibitor, protected PC12
cells from 6-OHDA-induced loss of cell viability in a dose-
dependent manner. These results may also indicate that the
protective effect of TSG on 6-OHDA-induced PC12 cell viability is
through prevention of elevation in intracellular NO levels.
Figure 4. Cell apoptosis and necrosis detected by flow cytometry. PC12 cells were incubated in drug-free medium (A) or medium containing
50 mM TSG (B) or 75 mM 6-OHDA (C) for 24 h; or cells were pretreated with 10 mM (D), 20 mM (E) or 50 mM (F) TSG for 24 h and then incubated in 6-
OHDA (75 mM) for an additional 24 h. The results shown in (G) are the mean and SE for three independent experiments.
doi:10.1371/journal.pone.0026055.g004
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As shown in Figure 7, protein-bound 3-NT was measured by a
competitive ELISA method with an anti-3-NT antibody. After 6-
OHDA treatment, the level of 3-NT increased approximately 4.5-
fold compared with the control group (P,0.01). TSG pretreated
cells showed a reverse effect in a dose-dependent manner in the
10, 20 and 50 mM ranges, compared with the 6-OHDA group.
TSG alone had no obvious effect on the protein-bound 3-NT
levels in PC12 cells.
7. Effects of TSG on the expression of nNOS and iNOS
Western blotting reflected that 6-OHDA induced a 3.2-fold
increase in the immunoreactivity of nNOS in PC12 cells
compared with control cells. Pre-treatment with TSG reduced
the expression of nNOS induced by 6-OHDA in a dose-dependent
manner (Figure 8A and C). Additionally, 6-OHDA induced a 3.5-
fold increase in the immunoreactivity of iNOS in PC12 cells.
Pretreatment with TSG reduced the expression of iNOS induced
by 6-OHDA in a dose-dependent manner (Figure 8B and D).
Treatment with 50 mM TSG alone had no obvious influence on
the expression of iNOS and nNOS in PC12 cells.
Discussion
Our study showed that exposure of PC12 cells to 75 mM6 -
OHDA for 24 h significantly reduced cell viability, induced typical
apoptosis features such as nuclei concentration, boosted the
percentage of apoptosis cells, increased the level of intracellular
ROS and NO, induced overexpression of iNOS and nNOS and
elevated the level of 3-NT. However, the above changes were
markedly reversed in a dose-dependent manner after the pre-
treatment of PC12 cells with different concentrations of TSG for
24 h, which suggests that TSG may protect PC12 cells from 6-
OHDA-induced apoptosis by regulation of ROS-NO pathway.
It is well known that the pathogenesis of age-related diseases
such as PD involves the generation of ROS [31]. The mechanism
of 6-OHDA toxicity is linked to production of extracellular ROS
via auto-oxidation and generation of intracellular ROS after being
taken up by PC12 cells [32–34]. The generation of intracellular
ROS by 6-OHDA is either by direct inhibition of mitochondrial
respiratory chain complexes I and IV or by enzymatic deamina-
tion through monoamine oxidase [35]. Moreover, the generation
of intracellular ROS by 6-OHDA is an initial event and the ROS
suppresses the Akt phosphorylation, increases p38 phosphorylation
which induces the activation of caspase-9 as well as caspase-3, and
finally leads to cell apoptosis [32]. These indicate that ROS plays
an important role in cell apoptosis induced by 6-OHDA [8]. Our
results showed that the level of intracellular ROS significantly
increased after PC12 cells were treated with 6-OHDA for 24 h.
However, the level of intracellular ROS decreased in a dose-
dependent manner when PC12 cells were pretreated with different
concentrations of TSG prior to 6-OHDA treatment.
Figure 5. Effect of TSG on 6-OHDA-induced accumulation of
intracellular ROS levels. Cells were pretreated with different
concentrations of TSG for 24 h and then incubated in 6-OHDA for an
additional 24 h. Intracellular ROS levels were measured using DCFH-DA.
Data are expressed as percentage of untreated control cells 6 standard
deviation (n=6). **P,0.01 versus untreated control cells; ## P,0.01
versus 6-OHDA-treated cells.
doi:10.1371/journal.pone.0026055.g005
Figure 6. Effect of TSG on 6-OHDA-induced accumulation of
intracellular NO (A). Cells were exposed to 6-OHDA with or without
different concentrations of TSG for 24 h. (B) Effect of L-NMMA on 6-
OHDA-induced cell viability in PC12 cells. Cells were pretreated with
different concentrations of L-NMMA for one hour and then incubated in
6-OHDA for an additional 24 h. Data are expressed as percentage of
untreated control cells 6 standard deviation (n=6). **P,0.01 versus
untreated control cells; ## P,0.01 versus 6-OHDA-treated cells.
doi:10.1371/journal.pone.0026055.g006
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reduced nicotinamide adenine dinucleotide phosphate and
molecular oxygen [36]. NO is a well known vasorelaxant agent,
while NO produced by neurons plays an important role as a
neurotransmitter and NO produced by immune and glial cells is
involved in defense functions [37]. In addition, in the brain,
metabolism of NO seems to be indispensable for normal cerebral
function such as pain perception, synaptic plasticity and learning.
However, NO may act as a neurotoxin and cause neuronal injury
and death when inappropriate/excessive NO is produced in the
brain [36,38–40]. Moreover, there is increasing evidence that NO
is involved in the pathogenesis of neurodegenerative diseases,
including PD [41–43]. To date, NOS has four known isoforms:
nNOS, iNOS, eNOS, and mitochondrial nitric oxide synthase
[37,44]. nNOS and iNOS are acknowledged to be closely related
to the pathogenesis of PD, for example, nNOS inhibitor has a
dose-dependent protective effect against 1-methyl-4- phenyl-
1,2,3,6- tetrahydropyridine (MPTP)-induced striatal dopamine
and 3,4- dihydroxyphenylacetic acid depletion in mice, and
dopaminergic neurons in the SNPc of iNOS-deficient mice were
almost completely protected from MPTP toxicity in a chronic
paradigm of MPTP toxicity [45,46]. Our Western blot analyses
showed that the expression of nNOS and iNOS proteins increased
after treatment of PC12 cells with 6-OHDA for 24 h. We also
found the level of intracellular NO to rise significantly after PC12
cells were treated with 6-OHDA for 24 h. Conversely, both the
Figure 7. Effect of TSG on 6-OHDA-induced elevation of
protein-bound 3-NT in PC12 cells. PC12 cells were exposed to
TSG (10, 20 or 50 mM) for 24 h before 75 mM 6-OHDA was added to the
medium for an additional 24 h, and then 3-NT was measured. Data are
expressed as percentage of untreated control cells 6 standard
deviation (n=5). **P,0.01 versus untreated control cells; # P,0.05,
## P,0.01 versus 6-OHDA-treated cells.
doi:10.1371/journal.pone.0026055.g007
Figure 8. Effect of TSG and 6-OHDA on the expression of nNOS and iNOS. PC12 cells were exposed to 75 mM 6-OHDA with or without
different concentrations of TSG for 24 h, and the nNOS (A) and the iNOS (B) were detected by Western blotting. (C) and (D) show the quantitative
analysis of nNOS and iNOS protein levels, respectively. Data obtained from quantitative densitometry were presented as mean 6 standard deviation
of three independent experiments. *P,0.05, **P,0.01 versus untreated control cells; # P,0.05, ## P,0.01 versus 6-OHDA treated cells.
doi:10.1371/journal.pone.0026055.g008
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iNOS proteins decreased in a dose-dependent manner after pre-
treatment of PC12 cells with different concentrations of TSG.
Additionally, inhibiting the generation of NO by L-NMMA can
partly counteract the decrease in cell viability induced by 6-
OHDA. These data suggest that NO plays an important role in
cell apoptosis induced by 6-OHDA. TSG, like L-NMMA, may
inhibit the generation of NO and decrease the level of cell
apoptosis induced by 6-OHDA.
NO can cause neuronal cell death though different pathways
including activation of p53, increase of endoplasmic reticulum
stress, activation of mitochondrial permeability transition and
subsequent release of cytochrome c, and activation of p38 or other
MAP kinase pathways [47]. Notably, excessive NO can react with
ROS rapidly enough to avoid the action of antioxidant systems,
forming peroxynitrite anion (ONOO-), which can inhibit or
damage the mitochondrial complexes I, II, IV and V, mitochon-
drial membrane, mitochondrial DNA and superoxide dismutase
and induce mitochondrial swelling and Ca2+ release, which
stimulates Ca2+-dependent enzymes and triggers apoptosis
[37,48–52]. Moreover, Guo et al. found that 6-OHDA elevated
the level of 3-NT in SH-SY5Y cells [6]. It is hard to detect
ONOO-, thus, the generation of ONOO- is usually measured by
levels of 3-NT, a footprint of ONOO- [53]. We found that 6-
OHDA elevated the level of 3-NT in PC12 cells, while the level of
3-NT decreased after pretreatment of PC12 cells with TSG.
In summary, our data indicate that TSG protects PC12 cells
from 6-OHDA-induced apoptosis. The protective effects of TSG
are mediated, at least in part, by regulating the ROS-NO
pathway. Our results suggest that TSG could be used as a
neuroprotective agent in the treatment of neurodegenerative
diseases.
Author Contributions
Conceived and designed the experiments: JC XZ. Performed the
experiments: LT XFL LZ XBL XS XUEL LJ. Analyzed the data: LT
XBL XZ JC. Contributed reagents/materials/analysis tools: XFL JT XBL
XS XZ. Wrote the paper: LT XZ JC.
References
1. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet
Neurol 5: 525–535.
2. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson’s
disease. Adv Neurol 45: 19–34.
3. Jellinger KA, Kienzl E, Rumpelmaier G, Paulus W, Riederer P, et al. (1993)
Iron and ferritin in substantia nigra in Parkinson’s disease. Adv Neurol 60:
267–272.
4. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, et al. (1994) Alterations in
glutathione levels in Parkinson’s disease and other neurodegenerative disorders
affecting basal ganglia. Ann Neurol 36: 348–355.
5. Smith MP, Cass WA (2007) GDNF reduces oxidative stress in a 6-
hydroxydopamine model of Parkinson’s disease. Neurosci Lett 412: 259–263.
6. Guo S, Bezard E, Zhao B (2005) Protective effect of green tea polyphenols on the
SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway.
Free Radic Biol Med 39: 682–695.
7. Ju MS, Lee P, Kim HG, Lee KY, Hur J, et al. (2010) Protective effects of
standardized Thuja orientalis leaves against 6-hydroxyl- dopamine-induced
neurotoxicity in SH-SY5Y cells. Toxicol In Vitro 24: 759–765.
8. Tian LL, Wang XJ, Sun YN, Li CR, Xing YL, et al. (2008) Salvianolic acid B,
an antioxidant from Salvia miltiorrhiza, prevents 6-hydroxydopamine-induced
apoptosis in SH-SY5Y cells. Int J Bio chem Cell Biol 40: 409–422.
9. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, et al. (2001) Molecular
pathways involved in the neurotoxicity of 6-OHAD, dopamine and MPTP:
contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 65:
135–172.
10. Feng L, Meng H, Wu F, Cheng B, He X, et al. (2008) Olfactory ensheathing cells
conditioned medium prevented apoptosis induced by 6-OHDA in PC12 cells through
modulation of intrinsic apoptotic pathways. Int J Dev Neurosci 26: 323–329.
11. Gorman AM, Szegezdi E, Quigney DJ, Samali A (2005) Hsp27 inhibits 6-
hydroxydopamine-induced cytochrome-c release and apoptosis in PC12 cells.
Biochem Biophys Res Commun 327: 801–810.
12. Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-
OHDA and MPTP. Cell Tissue Res 318: 215–224.
13. Mayo JC, Sainz RM, Antolı ´n I, Rodriguez C (1999) Ultrastructural
confirmation of neuronal protection by melatonin against the neurotoxin 6-
hydroxydopamine cell damage. Brain Res 818: 221–227.
14. Walkinshaw G, Waters CM (1994) Neurotoxin-induced cell death in neuronal
PC12 cells is mediated by induction of apoptosis. Neuroscience 63: 975–987.
15. Chan YC, Wang MF, Chang HC (2003) Polygonum multiflorum extracts
improve cognitive performance in senescence accelerated mice. Am J Chin Med
31: 171–179.
16. Li X, Matsumoto K, Murakami Y, Tezuka Y, Wu Y, et al. (2005)
Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic
degeneration induced by paraquat and manebin mice. Pharmacol Biochem
Behav 82: 345–352.
17. Yang X (1996) Effect of ethanolic extract from root tuber of polygonummultif lorum
Thunb on liver and brain monoamine oxidase in senescenceaccelerated mice in
vivo. Zhongguo Zhong Yao Za Zhi 21: 48–49.
18. Chen Y, Wang M, Rosen RT, Ho CT (1999) 2,2-Diphenyl-1-picrylhydrazyl
radical-scavenging active components from Polygonum multiflorum Thunb. J Agric
Food Chem 47: 2226–2228.
19. Yao S, Li Y, Kong L (2006) Preparative isolation and purification of chemical
constituents from the root of Polygonum multiflorum by high-speed counter-
current chromatography. J Chromatogr A 1115: 64–71.
20. Ye S, Tang L, Xu J, Liu Q, Wang J (2006) Postconditioning’s protection of
THSG on cardiac ischemia-reperfusion injury and mechanism. J Huazhong
Univ Sci Technolog Med Sci 26: 13–16.
21. Zhang YZ, Shen JF, Xu JY, Xiao JH, Wang JL (2007) Inhibitory effects of
2,3,5,49-tetrahydroxystilbene-2-O-beta-D-glucoside on experimental inflamma-
tion and cyclooxygenase 2 activity. J Asian Nat Prod Res 9: 355–363.
22. Zhang L, Xing Y, Ye CF, Ai HX, Wei HF, et al. (2006) Learning-memory
deficit with aging in APP transgenic mice of Alzheimer’s disease and intervention
by using tetrahydroxystilbene glucoside. Behav Brain Res 173: 246–54.
23. Luo HB, Yang JS, Shi XQ, Fu XF, Yang QD (2009) Tetrahydroxy stilbene
glucoside reduces the cognitive impairment and overexpression of amyloid
precursor protein induced by aluminum exposure. Neurosci Bull 25: 391–396.
24. Wang T, Gu J, Wu PF, Wang F, Xiong Z, et al. (2009) Protection by
tetrahydroxystilbene glucoside against cerebral ischemia: involvement of JNK,
SIRT1, and NF-kappaB pathways and inhibition of intracellular ROS/RNS
generation. Free Radic Biol Med 47: 229–240.
25. Li X, Li Y, Chen J, Sun J, Li X, et al. (2010) Tetrahydroxystilbene glucoside
attenuates MPP
+-induced apoptosis in PC12 cells by inhibiting ROS generation
and modulating JNK activation. Neurosci Lett 483: 1–5.
26. Qin R, Li X, Li G, Tao L, Li Y, et al. (2011) Protection by tetrahydroxystilbene
glucoside against neurotoxicity induced by MPP
+: The involvement of PI3K/
Akt pathway activation. Toxicol Lett 202: 1–7.
27. Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW, et al.
(2002) Propargylamines induce antiapoptotic new protein synthesis in serum-
and nerve growth factor (NGF)-withdrawn. NGF-differentiated PC12 cells.
J Pharmacol Exp Ther 301: 753–764.
28. Liu B, Wang K, Gao HM, Mandavilli B, Wang JY, et al. (2001) Molecular
consequences of activated microglia in the brain: overactivation induces
apoptosis. J Neurochem 77: 182–189.
29. Kojima H, Urano Y, Kikuchi K, Higuchi T, Hirata Y, et al. (1999) Fluorescent
Indicators for Imaging Nitric Oxide Production. Angew Chem Int Ed Engl 38:
3209–3212.
30. Bharat S, Cochran BC, Hsu M, Liu J, Ames BN, et al. (2002) Pre-treatment with
R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications
for Parkinson’s disease therapy. Neurotoxicology 23: 479–486.
31. Keller JN, Dimayuga E, Chen Q, Thorpe J, Gee J, et al. (2004) Autophagy,
proteasomes, lipofuscin, and oxidative stress in the aging brain. Int J Biochem
Cell Biol 36: 2376–2391.
32. Fujita H, Ogino T, Kobuchi H, Fujiwara T, Yano H, et al. (2006) Cell-
permeable cAMP analog suppresses 6-hydroxydopamine- induced apoptosis in
PC12 cells through the activation of the Akt pathway. Brain Res 1113: 10–23.
33. Padiglia A, Medda R, Lorrai A, Biggio G, Sanna E, et al. (1997) Modulation of
6-hydroxydopamine oxidation by various proteins. Biochem Pharmacol 53:
1065–108.
34. Yamada K, Umegaki H, Maezawa I, Iguchi A, Kameyama T, et al. (1997)
Possible involvement of catalase in the protective effect of interleukin-6 against 6-
hydroxydopamine toxicity in PC12 cells. Brain Res Bull 43: 573–577.
35. Nie G, Jin C, Cao Y, Shen S, Zhao B (2002) Distinct effects of tea catechins on
6-hydroxydopamine-induced apoptosis in PC12 cells. Arch Biochem Biophys
397: 84–90.
36. Zhang L, Dawson VL, Dawson TM (2006) Role of nitric oxide in Parkinson’s
disease. Pharmacol Ther 109: 33–41.
37. Guix FX, Uribesalgo I, Coma M, Mun ˜oz FJ (2005) The physiology and
pathophysiology of nitric oxide in the brain. Prog Neurobiol 76: 126–152.
Effects of Tetrahydroxystilbene Glucoside
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e2605538. Duncan AJ, Heales SJ (2005) Nitric oxide and neurological disorders. Mol
Aspects Med 26: 67–96.
39. Dawson TM, Dawson VL, Snyder SH (1992) A novel neuronal messenger
molecule in brain: the free radical, nitric oxide. Ann Neurol 32: 297–311.
40. Heales SJ, Bolan ˜os JP, Stewart VC, Brookes PS, Land JM, et al. (1999) Nitric
oxide, mitochondria and neurological disease. Biochim Biophys Acta 1410:
215–228.
41. Torreilles F, Salman-Tabcheh S, Gue ´rin M, Torreilles J (1999) Neurodegen-
erative disorders: the role of peroxynitrite. Brain Res Brain Res Rev 30:
153–163.
42. Boje KM (2004) Nitric oxide neurotoxicity in neurodegenerative diseases. Front
Biosci 9: 763–776.
43. Gatto EM, Riobo ´ NA, Carreras MC, Scho ¨pfer FJ, Pargament GA, et al. (1999)
Circulating plasma factors in Parkinson’s disease enhance nitric oxide release of
normal human neutrophils. J Neurol Sci 165: 66–70.
44. Chung KK, David KK (2010) Emerging roles of nitric oxide in neurodegen-
eration. Nitric Oxide 22: 290–295.
45. Watanabe H, Muramatsu Y, Kurosaki R, Michimata M, Matsubara M, et al.
(2004) Protective effects of neuronal nitric oxide synthase inhibitor in mouse
brain against MPTP neurotoxicity: an immunohistological study. Eur Neuropsy-
chopharmacol 14: 93–104.
46. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB (2000) Deficiency of
inducible nitric oxide synthase protects against MPTP toxicity in vivo.
J Neurochem 74: 2213–2216.
47. Brown GC (2010) Nitric oxide and neuronal death. Nitric Oxide 23: 153–165.
48. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990) Apparent
hydroxyl radical production by peroxynitrite: implications for endothelial injury
from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620–1624.
49. Brown GC (1999) Nitric oxide and mitochondrial respiration. Biochim Biophys
Acta 1411: 351–369.
50. Castillo MR, Babson JR (1998) Ca
2+-dependent mechanisms of cell injury in
cultured cortical neurons. Neuroscience 86: 1133–1144.
51. Godber BL, Doel JJ, Sapkota GP, Blake DR, Stevens CR, et al. (2000)
Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol
Chem 275: 7757–7763.
52. Koppenol WH, Moreno JJ, Pryor WA, Ischiropoulos H, Beckman JS (1992)
Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide. Chem
Res Toxicol 5: 834–842.
53. Althaus JS, Schmidt KR, Fountain ST, Tseng MT, Carroll RT, et al. (2000) LC-
MS/MS detection of peroxynitrite-derived 3-nitrotyrosine in rat microvessels.
Free Radic Biol Med 29: 1085–1095.
Effects of Tetrahydroxystilbene Glucoside
PLoS ONE | www.plosone.org 9 October 2011 | Volume 6 | Issue 10 | e26055